Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 20/20 | 1.00 |
| ▸ | HTR2A | P28223 | 5/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.72 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL5697699 | 0.92 | SLC6A4 (0.84) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL20852479 | 0.86 | SLC6A4 (0.76) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL6151816 | 0.85 | SLC6A4 (0.74) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL19361260 | 0.82 | SLC6A4 (0.77) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL16216154 | 0.82 | SLC6A4 (1.00) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL16216185 | 0.82 | SLC6A4 (0.77) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL9121785 | 0.81 | SLC6A4 (1.00) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL18401370 | 0.81 | SLC6A4 (0.75) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL6947037 | 0.81 | SLC6A4 (1.00) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL6946108 | 0.81 | SLC6A4 (1.00) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | ZALICUS INC. | 2011-02-03 | — | — | US | disclosed |
| US-20100092479-A1 | Compositions and methods for treatment of viral diseases | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-04-15 | — | — | US | disclosed |
| WO-2010021681-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-02-25 | — | — | WO | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| EP-1268396-B1 | DIPHENYL ETHER COMPOUNDS USEFUL IN THERAPY | PFIZER LTD (GB) | 2005-07-20 | — | — | EP | disclosed |
| US-20050119504-A1 | New process for the preparation of a biphenyl ether compound | PFIZER INC | 2005-06-02 | — | — | US | disclosed |
| US-6448293-B1 | TREATMENT OR PREVENTION OF A DISORDER IN WHICH THE REGULATION OF MONOAMINE TRANSPORTER FUNCTION IS IMPLICATED, SUCH AS PREMATURE EJACULATION. | PFIZER INC. | 2002-09-10 | — | — | US | disclosed |
| US-20020052395-A1 | Diphenyl ether compounds useful in therapy | ANDREWS MARK DAVID (GB) | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | SLC6A4 34/4885HTR2A 10/4885KCNH2 1523/4885 |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | SLC6A4 4537/4885HTR2A 4618/4885KCNH2 2148/4885 |
| US-20020052395-A1 | Diphenyl ether compounds useful in therapy | CBR1, OGFR, CBR3 | SLC6A4 2002/4885HTR2A 1502/4885KCNH2 438/4885 |
| US-20100092479-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, RNASE1, EIF2AK2 | SLC6A4 4825/4885HTR2A 3555/4885KCNH2 1927/4885 |
| US-20050119504-A1 | New process for the preparation of a biphenyl ether compound | TPH1, SLC6A4, HTR4 | SLC6A4 2/4885HTR2A 24/4885KCNH2 1895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.